NATIONAL JEWISH HEALTH

• TRIAD NATIONAL SECURITY, LLC

  UEI X7WUS5LRBQU3

  $700K

  Subcontractor to this prime · 1 sub-award · latest Mar 6, 2025

  • Department of Energy
  • “NATIONAL JEWISH HEALTH-STAND ALONE-ITEM LEVEL-EMPLOYEE BENEFITS, BUSINESS INSURANCE AND ANCILLARY SERVICES (PENSION, RETIREE MEDICAL, ACTUARIAL, ETC.)”

• BRIGHAM & WOMENS HOSPITAL INC

  UEI QN6MS4VN7BD1

  $4.1M

  Subcontracted by this company · 2 sub-awards · latest Nov 20, 2024

  • National Institutes of Health
  • “BWH INVESTIGATORS WILL PARTICIPATE IN TASK A FOR ALL FIVE YEARS OF THE COPDGENE. PHASE 4 PROJECT AND WILL PROVIDE KEY CONTRIBUTIONS TO BOTH SPECIFIC AIMS OF THE TECHNICAL PROPOSAL. BWH WILL LEAD THE BWH COMPONENT OF THE COPDGENE ADMINISTRATIVE CENTER.”
  • “THE SUB PI AND OTHER BWH INVESTIGATORS WILL PARTICIPATE IN TASK A FOR ALL FIVE YEARS OF THE COPDGENE PHASE 4 PROJECT AND WILL PROVIDE KEY CONTRIBUTIONS TO BOTH SPECIFIC AIMS OF THE TECHNICAL PROPOSAL. HE WILL LEAD THE BWH COMPONENT OF THE COPDGENE ADMINISTRATIVE CENTER AS WELL AS THE GENETIC ANALYSIS CENTER. THE OTHER BWH INVESTIGATOR WILL DIRECT THE BIOINFORMATICS CENTER, WHICH WILL PERFORM OMICS DATA ANALYSIS WITH STATISTICAL, MACHINE LEARNING, AND NETWORK APPROACHES. SAN JOSE ESTEPAR WILL LEAD THE BWH COMPONENT OF THE COPDGENE IMAGING CENTER, WHICH WILL FOCUS ON LOCAL EMPHYSEMA PROGRESSION AND COMORBIDITY (CARDIAC, PULMONARY VASCULAR, AND PECTORALIS MUSCLE) MEASURES IN COPDGENE CT SCANS. NWH INVESTIGATORS WILL CONTINUE TO CO-LEAD THE COPDGENE SUBTYPING CENTER. THE COPDGENE BIOREPOSITORY STAFF AT BWH WILL WORK WITH BWH INVESTIGATORS TO PROVIDE QUALITY-CONTROLLED GENOMIC AND MOLECULAR DATA FROM COPDGENE BIOSPECIMENS COLLECTED DURING ALL STUDY VISITS. THE LEAD PI AND THE BWH CO-INVESTIGATORS WILL PARTICIPATE IN MULTIPLE WEEKLY CALLS AND REGULAR COPDGENE INVESTIGATOR MEETINGS TO DISCUSS TASK A ACTIVITIES.”
• THE REGENTS OF THE UNIVERSITY OF COLORADO

  UEI MW8JHK6ZYEX8 · not in the directory yet

  $534.6K

  Subcontracted by this company · 1 sub-award · latest Oct 4, 2024

  • National Institutes of Health
  • “THE SUB SITE PIS AT THE UNIVERSITY OF COLORADO DENVER (ANSCHUTZ CAMPUS) AND THEIR TEAM ARE THE EPIDEMIOLOGY CENTER FOR COPDGENE. THIS EPIDEMIOLOGY CENTER IS A CRITICAL COMPONENT OF COPDGENE AND SHARES RESPONSIBILITY FOR COMPLETION OF THE GENERAL SPECIFIC AIMS OF THIS STUDY. THIS INCLUDES PARTICIPATION IN THE FOLLOWING GROUPS: CLINICAL EPIDEMIOLOGY, COVID-19, CLINICAL TRANSLATION, COPDGENE 2024, ANCILLARY STUDIES AND PUBLICATIONS, AND THE EXECUTIVE COMMITTEE. THIS GROUP IS RESPONSIBLE FOR COPDGENE DATA ANALYSIS IN THE FIELD OF EPIDEMIOLOGY. A PRIMARY FOCUS OF THIS EPIDEMIOLOGY IS REFINEMENT OF THE AIRWAY-PREDOMINANT AND EMPHYSEMA-PREDOMINANT SUBTYPES OF COPD. THIS IS A CENTRAL GOAL OF COPDGENE AND INCLUDES ANALYSIS OF DIFFERENTIAL DISEASE PROGRESSION AND MORTALITY EXPERIENCED BY THESE CLINICALLY RELEVANT SUBTYPES. THE TEAM WILL USE ‘OMICS DATA TO IDENTIFY GENETIC AND BIOLOGICAL DETERMINANTS FOR THE SUSCEPTIBILITY OF THE DIFFERENT SUBTYPES OF COPD. THE TEAM WILL ALSO HAVE RESPONSIBILITY TO IDENTIFY DISTINCT TREATMENT PATTERNS, INCLUDING COMORBIDITIES, WHICH INFLUENCE THE DEVELOPMENT ANDPROGRESSION OF AIRWAY-PREDOMINANT AND EMPHYSEMA-PREDOMINANT SUBTYPES. THE TEAM WILL ALSO CONTINUE ITS WORK IDENTIFYING SMOKING PATTERNS AND BEHAVIOR AND IDENTIFY PATHOPHYSIOLOGIC AND SOCIAL INFLUENCES ON THE AIRWAY-PREDOMINANT AND EMPHYSEMA-PREDOMINANT SUBTYPES OF COPD.”
• THE CLEVELAND CLINIC FOUNDATION

  UEI TDGUJ1WA4UJ9

  $524.6K

  Subcontracted by this company · 1 sub-award · latest Oct 21, 2026

  • National Institutes of Health
  • “THE BIOMARKER CENTER WILL CREATE A PANEL OF APPROXIMATELY 15 PROTEIN BIOMARKERS CORRELATING WITH CLINICAL INDICES OF DISEASE PROGRESSION, PATTERNS OF DISEASE PROGRESSION, AND OTHER OMICS PROFILES. EXAMPLES OF THESE BIOMARKERS INCLUDE: SRAGE, IL-6, IL-8, FSH, LH, LEPTIN, SLPI, MBL, VEGF, ANGIOGENIN, ST2, CSRPD, TROPONIN, KALLIKREIN, BMPR1A, RGM-C, LYMPHOCYTE ACTIVATION GENE 3, EMR2, ETC. THESE CANDIDATE BIOMARKERS WILL BE USED TO CREATE A MESO SCALE DISCOVERY (MSD) V-, R-, U-PLEX PANELS. SAMPLES WILL BE RUN IN DUPLICATE AND THOSE WITH CV > 10% WILL BE RERUN. THE SELECTION OF BIOMARKERS WILL BE BASED ON RECENT LITERATURE REVIEW (SERBAN KA, PRATTE KA, BOWLER RP. "PROTEIN BIOMARKERS FOR COPD OUTCOMES". CHEST. 2021 PMID: 33434499) AND RECENTLY COMPLETED SOMASCAN ANALYSIS OF COPDGENE SAMPLES. BIOMARKERS THAT ARE NOT AVAILABLE ON MSD PANEL MAY BE AVAILABLE AS ELISA OR THE SOMAMER ASSAYS CAN BE USED TO CREATE CUSTOM PANELS. THE PANEL OF BIOMARKERS WILL THEN BE VALIDATED OVER FOUR YEARS IN 500 SAMPLES/PER YEAR ALIQUOTS.”
• DARTNET INSTITUTE

  UEI DK14XRAKRKK1

  $60.6K

  Subcontracted by this company · 1 sub-award · latest Jun 18, 2026

  • National Institutes of Health
  • “THE SUBCONTRACT PI WILL WORK WITH THE EXECUTIVE COMMITTEE AND CLINICAL CENTER MANAGEMENT WHILE INTERFACING WITH MOST STUDY ACTIVITIES.”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.